November 9, 2022- Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.
Contact details
-
Download vCard
- Sarah Martin-Tyrrell
-
KBI Biopharma Company Inquiries
Senior Manager, PR and Content - sarah.martin-tyrrell@crownbio.com
-
Download vCard
- Sarah Martin-Tyrrell
-
JSR Life Sciences Company Inquiries
Senior Manager, PR and Content - sarah.martin-tyrrell@crownbio.com
Copy link
https://news.jsrlifesciences.com/220103-tim-lowery-appointed-interim-ceo-of-kbi-and-selexisRelated topics
Related news
KBI Biopharma Awarded as Global Leader in Biologics Manufacturing
KBI Biopharma, a JSR Life Sciences company, wins global recognition for excellence in biologics manufacturing at the 2025 CDMO Leadership Awards.
KBI Biopharma to Lead Development and Manufacturing of Alanis Therapeutics’ Antagonistic Monoclonal Antibody Candidate
KBI Biopharma Selected as CDMO of Choice to Fast-Track Development of Pre-Clinical Antibody for Blood Cancers Using SUREmAbTM Technology
Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Phar...
Extension reinforces KBI’s commitment to forge long-term partnerships to successfully address complex clinical development and commercialization challenges.
KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality...
KBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceu...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract man...